Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses

por Tashkin, Donald P., Chipps, Bradley E., Trudo, Frank, Zangrilli, James G.
Publicado 2014

Postbronchodilator lung function improvements with benralizumab for patients with severe asthma

por Mathur, Sameer K., Modena, Brian D., Coumou, Hanneke, Barker, Peter, Kreindler, James L., Zangrilli, James G.
Publicado 2020

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab

por Jackson, David J., Korn, Stephanie, Mathur, Sameer K., Barker, Peter, Meka, Venkata G., Martin, Ubaldo J., Zangrilli, James G.
Publicado 2020

Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma

por Park, Hae-Sim, Lee, Sang Haak, Lee, Sook Young, Kim, Mi-Kyeong, Lee, Byung Jae, Werkström, Viktoria, Barker, Peter, Zangrilli, James G.
Publicado 2019

Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and β(2)-agonist use

por Hastie, Annette T, Wu, Min, Foster, Gayle C, Hawkins, Gregory A, Batra, Vikas, Rybinski, Katherine A, Cirelli, Rosemary, Zangrilli, James G, Peters, Stephen P
Publicado 2006

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

por Bleecker, Eugene R., Wechsler, Michael E., FitzGerald, J. Mark, Menzies-Gow, Andrew, Wu, Yanping, Hirsch, Ian, Goldman, Mitchell, Newbold, Paul, Zangrilli, James G.
Publicado 2018